TDI-11055
Product Specifications
UNSPSC Description
TDI-11055 is an inhibitor of the epigenetic reader protein 11-19 leukemia (ENL) YEATS, which drives the oncogenic transcriptional program of acute myeloid leukemia (AML), the hematopoietic malignancy AML[1].
Target Antigen
Endogenous Metabolite
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
cancer
Assay Protocol
https://www.medchemexpress.com/tdi-11055.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C[C@H]1CCCN1CC2=CC3=C(N2)C=C(N=C3)NC(C4=CC=C5C(C=NN5C)=C4)=O
Molecular Weight
388.47
References & Citations
[1]Michino M, et al. Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable In Vivo Studies: Discovery of TDI-11055[J]. ACS Medicinal Chemistry Letters, 2024.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-162350/TDI-11055-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-162350/TDI-11055-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
OR1067260-01 25 mg
N- (3-Bromophenyl) -4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide
Ask
View Details OR1067260-02 50 mg
N- (3-Bromophenyl) -4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide
Ask
View Details 
OR1067260-03 100 mg
N- (3-Bromophenyl) -4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide
Ask
View Details OR1067260-04 250 mg
N- (3-Bromophenyl) -4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide
Ask
View Details